Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PRKCA | P17252 | 4/20 | 0.65 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL180497 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL6433273 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL56526 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL2115585 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL629793 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL1173235 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL141667 | 1.00 | LMNA (0.66) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL9160363 | 0.98 | LMNA (0.64) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Ethylene Glycol SCHEMBL12489211 | 0.98 | LMNA (0.63) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Butane SCHEMBL3900185 | 0.97 | LMNA (0.61) | LMNAALDH1A1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137627-A1 | ENCAPSULATION OF POORLY WATER SOLUBLE COMPOUNDS USING OSA-MODIFIED NON-STARCH POLYSACCHARIDES | KANSAS STATE UNIV RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743053-A1 | ANTIMICROBIAL SYNERGIES | Symrise AG (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4554551-B1 | 3-HYDROXYPROPYLESTERS AS ANTIMICROBIAL AGENTS | SYMRISE AG (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-4701417-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A CATIONIC ANTIMICROBIAL AND AN ACIDIC GLYCOLIPID | LANXESS Corporation (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4687850-A1 | ORAL DRUG DOSAGE FORMS FOR COLON DELIVERY AND METHODS OF USE AND MAKING THEREOF | Triastek, Inc. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20260027123-A1 | Compositions for Modulating Lipoxygenase and Methods of Using Same | UNIV CALIFORNIA (US) | 2026-01-29 | — | — | US | claimed |
| US-12377039-B2 | Cleansing compositions | L'OREAL (FR) | 2025-08-05 | — | — | US | claimed |
| CN-120131658-A | Tadalafil self-emulsifying dispersible tablet and preparation method thereof | 深圳海王医药科技研究院有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120091817-A | Orbicifacipimox and ezetimibe combination therapy and fixed dose pharmaceutical composition | 新阿姆斯特丹制药私人有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4558508-A1 | COMPOSITIONS FOR MODULATING LIPOXYGENASE AND METHODS OF USING SAME | The Regents of the University of California (US) | 2025-05-28 | — | — | EP | claimed |
| WO-2008032995-A1 | CLOPIDOGREL(+)-CAMPHORSULFONATE SALT, METHOD OF PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2008-03-20 | — | — | WO | claimed |
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-08-23 | — | — | US | claimed |
| WO-2007087806-A1 | A TOPICAL COMPOSITION COMPRISING AN ANTIBACTERIAL SUBSTANCE | LEO PHARMA A/S (DK) | 2007-08-09 | — | — | WO | claimed |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-06-21 | — | — | US | claimed |
| WO-2006059221-A2 | TOPICAL HYDRO-ALCOHOLIC FORMULATIONS OF OXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-06-08 | — | — | WO | claimed |
| CN-1211085-C | Compositions having improved stability | PROCTER & GAMBLE (US) | 2005-07-20 | — | — | CN | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | claimed |
| US-5744137-A | WATER IN OIL EMULSION VACCINE HAVING ANTIGEN DIRECTLY EMULSIFIED INTO OIL PHASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AGRICULTURE (US) | 1998-04-28 | — | — | US | claimed |
| WO-1996024374-A1 | OIL EMULSION VACCINES PREPARED WITH ANIMAL, VEGETABLE, AND SYNTHETIC OILS USING A MIXTURE OF NONIONIC SURFACTANTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF AGRICULTURE (US) | 1996-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | LIPA, CUTA, LIPG | LMNA 388/4885ALDH1A1 2486/4885PRKCA 2438/4885 |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | CUTA, ELOVL1, LIPA | LMNA 483/4885ALDH1A1 2197/4885PRKCA 3394/4885 |
| US-20260137627-A1 | ENCAPSULATION OF POORLY WATER SOLUBLE COMPOUNDS USING OSA-MODIFIED NON-STARCH POLYSACCHARIDES | BSG, GYS1, CHIT1 | LMNA 3067/4885ALDH1A1 2759/4885PRKCA 1522/4885 |
| US-20260027123-A1 | Compositions for Modulating Lipoxygenase and Methods of Using Same | ALOX12, ALOX15, ALOX15B | LMNA 404/4885ALDH1A1 1256/4885PRKCA 828/4885 |
| US-12377039-B2 | Cleansing compositions | SMURF1, SMURF2, SGMS2 | LMNA 1086/4885ALDH1A1 2047/4885PRKCA 1868/4885 |
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | LMNA 3268/4885ALDH1A1 3124/4885PRKCA 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.